What happens to drug use and expenditure when cost sharing is completely removed? Evidence from a Canadian provincial public drug plan

Tracey-Lea Laba, Lucy Cheng, Heather C. Worthington, Kimberlyn M. McGrail, Fiona K.I. Chan, Muhammad Mamdani and Michael R. Law

Health Policy, 2020, vol. 124, issue 9, 977-983

Abstract: The role of cost-sharing for medicines is under active policy discussion, including in proposals for value-based insurance design. To inform this debate, we estimated the impact of completely removing cost-sharing on medication use and expenditure using a quasi-experimental approach.

Keywords: Cost sharing; Drug policy; Interrupted time series; Canada (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851018305876
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:124:y:2020:i:9:p:977-983

DOI: 10.1016/j.healthpol.2020.05.001

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().